Pub Date : 2024-10-31eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1453166
EnRun Wang, YuanJing Li, Gang Yu, Gang Liu, Jiang Deng, YanFei Wang, Wei Yang, GuoDong Chen, Dennis W Zhu, FengPeng Jia
Background: There have been few instances of symptomatic bradycardia-arrhythmia in the context of area postrema syndrome (APS), and some of them have been implanted permanent pacemakers. Cardioneuroablation (CNA) has emerged as a viable therapy for the treatment of syncope induced by neutrally mediated bradycardia or atrioventricular block.
Methods: We report a young patient with recurrent cardiac asystole and syncope following persistent hiccups caused by neuromyelitis optica spectrum disorder (NMOSD), who successfully completed CNA treatment and avoided permanent pacemaker placement. We also summarized and analyzed 20 previously reported cases that were relevant to APS with bradyarrhythmia.
Results: In a patient with NMOSD, CNA can efficiently and safely eradicate symptomatic bradycardia-arrhythmia. A total of 21 cases were identified in the final analysis (including our case). The average age was 51 years old and female patients accounted for 38.1%. Brady-arrhythmia was presented in all patients, and 9 patients were implanted temporary or permanent pacemakers. 4 of the 9 patients were received permanent pacing therapy because they were not weaned off pacing support after etiological treatment.
Conclusions: Cardiac asystole and syncope after persistent hiccups may be the first signs of APS of medullary lesions, and CNA may be a useful therapy option for these patients in experienced centers. We believe that in this scenario, CNA may be a superior therapeutic option than permanent pacemaker placement. Additionally, the statement also serves as a cautionary reminder for health care professionals to establish an association between bradyarrhythmia and APS of medullary lesions in their clinical practice.
{"title":"Cardioneuroablation eliminating cardiac asystole associated with area postrema syndrome: a case report and literature review.","authors":"EnRun Wang, YuanJing Li, Gang Yu, Gang Liu, Jiang Deng, YanFei Wang, Wei Yang, GuoDong Chen, Dennis W Zhu, FengPeng Jia","doi":"10.3389/fcvm.2024.1453166","DOIUrl":"10.3389/fcvm.2024.1453166","url":null,"abstract":"<p><strong>Background: </strong>There have been few instances of symptomatic bradycardia-arrhythmia in the context of area postrema syndrome (APS), and some of them have been implanted permanent pacemakers. Cardioneuroablation (CNA) has emerged as a viable therapy for the treatment of syncope induced by neutrally mediated bradycardia or atrioventricular block.</p><p><strong>Methods: </strong>We report a young patient with recurrent cardiac asystole and syncope following persistent hiccups caused by neuromyelitis optica spectrum disorder (NMOSD), who successfully completed CNA treatment and avoided permanent pacemaker placement. We also summarized and analyzed 20 previously reported cases that were relevant to APS with bradyarrhythmia.</p><p><strong>Results: </strong>In a patient with NMOSD, CNA can efficiently and safely eradicate symptomatic bradycardia-arrhythmia. A total of 21 cases were identified in the final analysis (including our case). The average age was 51 years old and female patients accounted for 38.1%. Brady-arrhythmia was presented in all patients, and 9 patients were implanted temporary or permanent pacemakers. 4 of the 9 patients were received permanent pacing therapy because they were not weaned off pacing support after etiological treatment.</p><p><strong>Conclusions: </strong>Cardiac asystole and syncope after persistent hiccups may be the first signs of APS of medullary lesions, and CNA may be a useful therapy option for these patients in experienced centers. We believe that in this scenario, CNA may be a superior therapeutic option than permanent pacemaker placement. Additionally, the statement also serves as a cautionary reminder for health care professionals to establish an association between bradyarrhythmia and APS of medullary lesions in their clinical practice.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1453166"},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aims to evaluate whether radiomic features of pericoronary adipose tissue (PCAT) derived from coronary computed tomography angiography (CCTA) can better predict major adverse cardiovascular events (MACE) in patients with angina pectoris.
Methods: A single-center retrospective study included 239 patients with angina pectoris who underwent coronary CT examinations. Participants were divided into MACE (n = 46) and non-MACE (n = 193) groups based on the occurrence of MACE during follow-up, and further allocated into a training cohort (n = 167) and a validation cohort (n = 72) at a 7:3 ratio. Automatic segmentation of PCAT surrounding the proximal segments of the left anterior descending artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA) was performed for all patients. Radiomic features of the coronary arteries were extracted, screened, and integrated while quantifying the fat attenuation index (FAI) for the three vessels. Univariate and multivariate logistic regression analyses were utilized to select clinical predictors of adverse cardiovascular events. Subsequently, machine learning techniques were employed to construct models based on FAI, clinical features, and radiomic characteristics. The predictive performance of each model was assessed and compared using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis for clinical utility.
Results: The radiomics model demonstrated superior performance in predicting MACE in patients with angina pectoris within both the training and validation cohorts, yielding areas under the curve (AUC) of 0.83 and 0.71, respectively, which significantly outperformed the FAI model (AUC = 0.71, 0.54) and the clinical model (AUC = 0.81, 0.67), with statistically significant differences in AUC (p < 0.05). Calibration curves for all three predictive models exhibited good fit (all p > 0.05). Decision curve analysis indicated that the radiomics model provided higher clinical benefit than the traditional clinical and FAI models.
Conclusion: The CCTA-based PCAT radiomics model is an effective tool for predicting MACE in patients with angina pectoris, assisting clinicians in optimizing risk stratification for individual patients. The CCTA-based radiomics model significantly surpasses traditional FAI and clinical models in predicting major adverse cardiovascular events in patients with angina pectoris.
{"title":"Predicting major adverse cardiovascular events in angina patients using radiomic features of pericoronary adipose tissue based on CCTA.","authors":"Weisheng Zhan, Yanfang Luo, Hui Luo, Zheng Zhou, Nianpei Yin, Yixin Li, Xinyi Feng, Ying Yang","doi":"10.3389/fcvm.2024.1462451","DOIUrl":"10.3389/fcvm.2024.1462451","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate whether radiomic features of pericoronary adipose tissue (PCAT) derived from coronary computed tomography angiography (CCTA) can better predict major adverse cardiovascular events (MACE) in patients with angina pectoris.</p><p><strong>Methods: </strong>A single-center retrospective study included 239 patients with angina pectoris who underwent coronary CT examinations. Participants were divided into MACE (<i>n</i> = 46) and non-MACE (<i>n</i> = 193) groups based on the occurrence of MACE during follow-up, and further allocated into a training cohort (<i>n</i> = 167) and a validation cohort (<i>n</i> = 72) at a 7:3 ratio. Automatic segmentation of PCAT surrounding the proximal segments of the left anterior descending artery (LAD), left circumflex coronary artery (LCX), and right coronary artery (RCA) was performed for all patients. Radiomic features of the coronary arteries were extracted, screened, and integrated while quantifying the fat attenuation index (FAI) for the three vessels. Univariate and multivariate logistic regression analyses were utilized to select clinical predictors of adverse cardiovascular events. Subsequently, machine learning techniques were employed to construct models based on FAI, clinical features, and radiomic characteristics. The predictive performance of each model was assessed and compared using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis for clinical utility.</p><p><strong>Results: </strong>The radiomics model demonstrated superior performance in predicting MACE in patients with angina pectoris within both the training and validation cohorts, yielding areas under the curve (AUC) of 0.83 and 0.71, respectively, which significantly outperformed the FAI model (AUC = 0.71, 0.54) and the clinical model (AUC = 0.81, 0.67), with statistically significant differences in AUC (<i>p</i> < 0.05). Calibration curves for all three predictive models exhibited good fit (all <i>p</i> > 0.05). Decision curve analysis indicated that the radiomics model provided higher clinical benefit than the traditional clinical and FAI models.</p><p><strong>Conclusion: </strong>The CCTA-based PCAT radiomics model is an effective tool for predicting MACE in patients with angina pectoris, assisting clinicians in optimizing risk stratification for individual patients. The CCTA-based radiomics model significantly surpasses traditional FAI and clinical models in predicting major adverse cardiovascular events in patients with angina pectoris.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1462451"},"PeriodicalIF":2.8,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-30eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1432923
Jamie Corroon, Ryan Bradley, Matthew A Allison, Igor Grant
Background: Observational evidence investigating associations between cannabis use and blood pressure and hypertension is inconsistent.
Methods: Cross-sectional data from 3,255 participants at Exam 6 (2016-2018) of the Multi-Ethnic Study of Atherosclerosis (MESA) were analyzed, including self-reported cannabis smoking patterns, standardized measures of systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP; BP collectively), and hypertension. ANCOVA and multivariable relative risk regression models were used to calculate adjusted means for BP and adjusted prevalence ratios (PRs) for prevalent hypertension.
Results: In fully adjusted ANCOVA models, a history of regular cannabis smoking, when compared to no history, was not significantly associated with increased SBP [mean difference: 0.1 mmHg (95% CI: -1.6-1.9)], DBP [mean difference: 0.5 mmHg (95% CI: -0.3-1.4)], PP [mean difference: -0.5 mmHg (95% CI: -1.8-0.9)], or prevalent hypertension [PR: 1.01 (95% CI: 0.93-1.10)]. Furthermore, no associations were observed for either the duration or recency (in the past month) of cannabis smoking or number of joint/pipe years. Models exploring potential interactions between a history of regular cannabis smoking and age, sex, race/ethnicity, and cigarette smoking status were not significant for either BP or hypertension.
Conclusions: In a cohort of racially and ethnically diverse older adults with a high prevalence of hypertension, no evidence of increased risk due to regular cannabis smoking was found for either blood pressure or hypertension.
{"title":"Blood pressure and hypertension in older adults with a history of regular cannabis use: findings from the Multi-Ethnic Study of Atherosclerosis.","authors":"Jamie Corroon, Ryan Bradley, Matthew A Allison, Igor Grant","doi":"10.3389/fcvm.2024.1432923","DOIUrl":"10.3389/fcvm.2024.1432923","url":null,"abstract":"<p><strong>Background: </strong>Observational evidence investigating associations between cannabis use and blood pressure and hypertension is inconsistent.</p><p><strong>Methods: </strong>Cross-sectional data from 3,255 participants at Exam 6 (2016-2018) of the Multi-Ethnic Study of Atherosclerosis (MESA) were analyzed, including self-reported cannabis smoking patterns, standardized measures of systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP; BP collectively), and hypertension. ANCOVA and multivariable relative risk regression models were used to calculate adjusted means for BP and adjusted prevalence ratios (PRs) for prevalent hypertension.</p><p><strong>Results: </strong>In fully adjusted ANCOVA models, a history of regular cannabis smoking, when compared to no history, was not significantly associated with increased SBP [mean difference: 0.1 mmHg (95% CI: -1.6-1.9)], DBP [mean difference: 0.5 mmHg (95% CI: -0.3-1.4)], PP [mean difference: -0.5 mmHg (95% CI: -1.8-0.9)], or prevalent hypertension [PR: 1.01 (95% CI: 0.93-1.10)]. Furthermore, no associations were observed for either the duration or recency (in the past month) of cannabis smoking or number of joint/pipe years. Models exploring potential interactions between a history of regular cannabis smoking and age, sex, race/ethnicity, and cigarette smoking status were not significant for either BP or hypertension.</p><p><strong>Conclusions: </strong>In a cohort of racially and ethnically diverse older adults with a high prevalence of hypertension, no evidence of increased risk due to regular cannabis smoking was found for either blood pressure or hypertension.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1432923"},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p><strong>Objectives: </strong>In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis (IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of coronary heart disease.</p><p><strong>Methods: </strong>In this multicenter randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency, IPBS combined with qi stagnation, and IPBS combined with toxin accumulation. The control group was treated with routine Western medicine. In addition to routine Western medicine treatment, the treatment group (the IPBS group) was treated with Danlou tablets or Danlou tablets supplemented by interventional therapies based on the results of traditional Chinese medicine differentiation. The frequency of angina attacks per week was the main efficacy evaluation indicator and the secondary efficacy evaluation indicators included angina symptom score, Seattle Angina Questionnaire, an electrocardiogram (ECG) efficacy evaluation, a cardiac Doppler two-dimensional ultrasound, an electrocardiogram treadmill exercise test, blood lipids, blood glucose, a coagulation function test, hemorheology indicators, homocysteine, C-reactive protein (CRP) or high sensitivity-CRP, TCM syndromes (syndrome score, tongue, pulse), and long-term prognosis (endpoint outcome, cardiovascular events).</p><p><strong>Results: </strong>There were 300 cases in the full analysis set (FAS), 266 in the per-protocol set (PPS), and 300 in the safety set. Regarding the main efficacy indicator, after treatment, the reduction in the frequency of weekly angina attacks in the treatment group was significantly greater than that in the control group (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. Regarding the secondary efficacy evaluation indicators, the angina symptom, TCM syndrome, ECG evaluation, Seattle Angina Pectoris Questionnaire, and 36-item Health Status Survey Summary Form scores of the treatment group were significantly higher than the control group (<i>P</i> < 0.05) and the homocysteine levels of the treatment group were significantly reduced (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. In the PPS, the triglyceride levels in the treatment group were significantly lower than those in the control group after treatment (<i>P</i> < 0.05). The activated partial thromboplastin time in the treatment group decreased significantly (<i>P</i> < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.
研究目的本研究评估了丹路片治疗痰瘀互结型稳定性心绞痛(SAP)的临床疗效和安全性,为冠心病的防治提供高质量的循证医学证据:在这项多中心随机对照研究中,来自中国12个国家中医临床研究中心的304名稳定型心绞痛伴痰瘀互结(IPBS)患者被随机分配到治疗组和对照组,两组的比例为1:1。每组根据中医证候分型结果分为四个亚组:IPBS、IPBS 合并气虚、IPBS 合并气滞、IPBS 合并毒素蓄积。对照组采用常规西药治疗。治疗组(IPBS 组)在常规西医治疗的基础上,根据中医分型结果,采用丹路片或丹路片辅以介入疗法进行治疗。主要疗效评价指标为每周心绞痛发作频率,次要疗效评价指标包括心绞痛症状评分、西雅图心绞痛问卷、心电图疗效评价、心脏多普勒二维超声检查、心电图跑步训练、心电图跑步机运动测试、血脂、血糖、凝血功能测试、血液流变学指标、同型半胱氨酸、C反应蛋白(CRP)或高敏CRP、中医综合征(综合征评分、舌象、脉象)和长期预后(终点结局、心血管事件)。结果:全分析组(FAS)有 300 例,按方案组(PPS)有 266 例,安全组有 300 例。在主要疗效指标方面,治疗后,治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P 结论:治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P 结论:治疗组心绞痛每周发作次数的减少幅度明显高于对照组(P P P P P丹鹿片和基于西医治疗的改良联合疗法能改善 SAP 和 IPBS 综合征及其并发症患者的心绞痛症状,提高患者的生活质量。临床试验注册:https://www.chictr.org.cn/showproj.html?proj=39724,ChiCTR注册,ChiCTR1900023708。
{"title":"Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicenter randomized controlled study.","authors":"Zeng Li, Han Li, Zheng Li, Yushi Zhou, Wei Yang, Yuhan Ao, Xinghua Xiang, Chongchai Li, Mingxue Zhang","doi":"10.3389/fcvm.2024.1462730","DOIUrl":"10.3389/fcvm.2024.1462730","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis (IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of coronary heart disease.</p><p><strong>Methods: </strong>In this multicenter randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency, IPBS combined with qi stagnation, and IPBS combined with toxin accumulation. The control group was treated with routine Western medicine. In addition to routine Western medicine treatment, the treatment group (the IPBS group) was treated with Danlou tablets or Danlou tablets supplemented by interventional therapies based on the results of traditional Chinese medicine differentiation. The frequency of angina attacks per week was the main efficacy evaluation indicator and the secondary efficacy evaluation indicators included angina symptom score, Seattle Angina Questionnaire, an electrocardiogram (ECG) efficacy evaluation, a cardiac Doppler two-dimensional ultrasound, an electrocardiogram treadmill exercise test, blood lipids, blood glucose, a coagulation function test, hemorheology indicators, homocysteine, C-reactive protein (CRP) or high sensitivity-CRP, TCM syndromes (syndrome score, tongue, pulse), and long-term prognosis (endpoint outcome, cardiovascular events).</p><p><strong>Results: </strong>There were 300 cases in the full analysis set (FAS), 266 in the per-protocol set (PPS), and 300 in the safety set. Regarding the main efficacy indicator, after treatment, the reduction in the frequency of weekly angina attacks in the treatment group was significantly greater than that in the control group (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. Regarding the secondary efficacy evaluation indicators, the angina symptom, TCM syndrome, ECG evaluation, Seattle Angina Pectoris Questionnaire, and 36-item Health Status Survey Summary Form scores of the treatment group were significantly higher than the control group (<i>P</i> < 0.05) and the homocysteine levels of the treatment group were significantly reduced (<i>P</i> < 0.05). The results of the FAS and PPS were consistent. In the PPS, the triglyceride levels in the treatment group were significantly lower than those in the control group after treatment (<i>P</i> < 0.05). The activated partial thromboplastin time in the treatment group decreased significantly (<i>P</i> < 0.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1462730"},"PeriodicalIF":2.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sick sinus syndrome (SSS) is a grave medical condition that can precipitate sudden death. The pathogenesis of SSS remains incompletely understood. Existing research postulates that the fundamental mechanism involves increased fibrosis of the sinoatrial node and its surrounding tissues, as well as disturbances in the coupled-clock system, comprising the membrane clock and the Ca2+ clock. Mitochondrial dysfunction exacerbates regional tissue fibrosis and disrupts the functioning of both the membrane and calcium clocks. This plays a crucial role in the underlying pathophysiology of SSS, including mitochondrial energy metabolism disorders, mitochondrial oxidative stress damage, calcium overload, and mitochondrial quality control disorders. Elucidating the mitochondrial mechanisms involved in the pathophysiology of SSS and further investigating the disease's mechanisms is of great significance.
{"title":"Mitochondrial dysfunction is a key link involved in the pathogenesis of sick sinus syndrome: a review.","authors":"Xinxin Shi, Liming He, Yucheng Wang, Yue Wu, Dongming Lin, Chao Chen, Ming Yang, Shuwei Huang","doi":"10.3389/fcvm.2024.1488207","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1488207","url":null,"abstract":"<p><p>Sick sinus syndrome (SSS) is a grave medical condition that can precipitate sudden death. The pathogenesis of SSS remains incompletely understood. Existing research postulates that the fundamental mechanism involves increased fibrosis of the sinoatrial node and its surrounding tissues, as well as disturbances in the coupled-clock system, comprising the membrane clock and the Ca<sup>2+</sup> clock. Mitochondrial dysfunction exacerbates regional tissue fibrosis and disrupts the functioning of both the membrane and calcium clocks. This plays a crucial role in the underlying pathophysiology of SSS, including mitochondrial energy metabolism disorders, mitochondrial oxidative stress damage, calcium overload, and mitochondrial quality control disorders. Elucidating the mitochondrial mechanisms involved in the pathophysiology of SSS and further investigating the disease's mechanisms is of great significance.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1488207"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-29eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1444466
Johannes Schlegl, Marwin Bannehr, Tanja Kücken, Paulina Jankowska, Michael Neuss, Michael Lichtenauer, Anja Haase-Fielitz, Christian Butter, Christoph Edlinger
Background: Severe tricuspid regurgitation is a progressive disease with an unfavourable prognosis. In recent years there have been extraordinary gains in knowledge through both clinical and basic scientific work. We performed a bibliometric analysis on tricuspid regurgitation with a focus on imaging techniques and treatment approaches and to identify scientific milestones and emerging research trends.
Methods: Publications, published between 2015 and 2023 were identified. Study characteristics, impact factors and countries of origin studies were recorded. Heat maps were created to visualise data and to identify leading centers. Most frequently cited publications were recognised as milestones.
Results: We screened 3,519 studies. 368 studies were included, of which 326 were clinical studies. Clinical studies were further subdivided into interventional (n = 138), surgical (n = 115) or studies on imaging modalities (n = 74). We detected an enormous increase in scientific output worldwide, especially in imaging and interventional studies. The United States, Germany and Poland were identified as leading countries in imaging, interventions and preclinical studies respectively.
Conclusions: Our study reflects the global gain in knowledge over the last 9 years. We were able to identify an annually rising number of interventional studies. Imaging studies have also seen a rapid increase, especially since 2020. In recent years, we monitored a decline in surgical studies.
{"title":"Bibliometric analysis of imaging and treatment strategies for severe tricuspid regurgitation from 2015 to 2023.","authors":"Johannes Schlegl, Marwin Bannehr, Tanja Kücken, Paulina Jankowska, Michael Neuss, Michael Lichtenauer, Anja Haase-Fielitz, Christian Butter, Christoph Edlinger","doi":"10.3389/fcvm.2024.1444466","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1444466","url":null,"abstract":"<p><strong>Background: </strong>Severe tricuspid regurgitation is a progressive disease with an unfavourable prognosis. In recent years there have been extraordinary gains in knowledge through both clinical and basic scientific work. We performed a bibliometric analysis on tricuspid regurgitation with a focus on imaging techniques and treatment approaches and to identify scientific milestones and emerging research trends.</p><p><strong>Methods: </strong>Publications, published between 2015 and 2023 were identified. Study characteristics, impact factors and countries of origin studies were recorded. Heat maps were created to visualise data and to identify leading centers. Most frequently cited publications were recognised as milestones.</p><p><strong>Results: </strong>We screened 3,519 studies. 368 studies were included, of which 326 were clinical studies. Clinical studies were further subdivided into interventional (<i>n</i> = 138), surgical (<i>n</i> = 115) or studies on imaging modalities (<i>n</i> = 74). We detected an enormous increase in scientific output worldwide, especially in imaging and interventional studies. The United States, Germany and Poland were identified as leading countries in imaging, interventions and preclinical studies respectively.</p><p><strong>Conclusions: </strong>Our study reflects the global gain in knowledge over the last 9 years. We were able to identify an annually rising number of interventional studies. Imaging studies have also seen a rapid increase, especially since 2020. In recent years, we monitored a decline in surgical studies.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1444466"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-29eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1433643
Shaobo Sun, Kang Xun, Damei Li, Renjie Bao
Introduction: Aspirin and indobufen are commonly used therapeutic drugs for the prevention of vascular restenosis (VR) after percutaneous transluminal angioplasty surgery. They both exhibited antiplatelet effects but molecular mechanisms underlying metabolic changes induced by them remain unclear.
Methods: In this study, we collected plasma samples from patients on aspirin medication (n = 5), patients on indobufen medication, patients with no medication after PTA, and healthy controls (CKs) (n = 5). Our investigation aimed to reveal the metabolic processes in patients during vascular restenosis and its amelioration through drug therapy using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Results: Our data showed significant alterations in amino acid and choline metabolism in patients without medication after PTA. Aspirin and indobufen were able to regulate these metabolic pathways to alleviate VR symptoms. We identified several characteristic amino acids, including pro-leu, L-citrulline, his-glu, and L-glutamate, as important biomarkers for VR assessment in patients without medication after PTA. A total of 17 and 4 metabolites involved in arginine and phenylalanine metabolism were specifically induced by aspirin and indobufen, respectively. Their expression levels were significantly regulated by aspirin or indobufen, nearly reaching normal levels.
Discussion: Taken together, our identification of metabolites involved in metabolic changes affected by aspirin and indobufen medication enhances the understanding of VR pathology after PTA. This may help identify early diagnostic biomarkers and therapeutic targets.
{"title":"Metabolomics revealed pharmacodynamic effects of aspirin and indobufen in patients after percutaneous transluminal angioplasty surgery.","authors":"Shaobo Sun, Kang Xun, Damei Li, Renjie Bao","doi":"10.3389/fcvm.2024.1433643","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1433643","url":null,"abstract":"<p><strong>Introduction: </strong>Aspirin and indobufen are commonly used therapeutic drugs for the prevention of vascular restenosis (VR) after percutaneous transluminal angioplasty surgery. They both exhibited antiplatelet effects but molecular mechanisms underlying metabolic changes induced by them remain unclear.</p><p><strong>Methods: </strong>In this study, we collected plasma samples from patients on aspirin medication (<i>n</i> = 5), patients on indobufen medication, patients with no medication after PTA, and healthy controls (CKs) (<i>n</i> = 5). Our investigation aimed to reveal the metabolic processes in patients during vascular restenosis and its amelioration through drug therapy using liquid chromatography-tandem mass spectrometry (LC-MS/MS).</p><p><strong>Results: </strong>Our data showed significant alterations in amino acid and choline metabolism in patients without medication after PTA. Aspirin and indobufen were able to regulate these metabolic pathways to alleviate VR symptoms. We identified several characteristic amino acids, including pro-leu, L-citrulline, his-glu, and L-glutamate, as important biomarkers for VR assessment in patients without medication after PTA. A total of 17 and 4 metabolites involved in arginine and phenylalanine metabolism were specifically induced by aspirin and indobufen, respectively. Their expression levels were significantly regulated by aspirin or indobufen, nearly reaching normal levels.</p><p><strong>Discussion: </strong>Taken together, our identification of metabolites involved in metabolic changes affected by aspirin and indobufen medication enhances the understanding of VR pathology after PTA. This may help identify early diagnostic biomarkers and therapeutic targets.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1433643"},"PeriodicalIF":2.8,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1445193
Amanda Husein, Jolie Boullion, Md Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, Md Shenuarin Bhuiyan, Gopi K Kolluru, Md Mostafizur Rahman Bhuiyan, Nicholas E Goeders, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan
Background: Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive form of pulmonary hypertension in which increased arterial pressure causes remodeling of the arterial system and is associated with heart failure. Methamphetamine is a stimulant that has recently become a focus in PAH research, but the recent trends and demographics of this cohort of patients are not known. The study aimed to analyze the overall trends and demographics of PAH patients with and without concurrent methamphetamine usage.
Methods: The study used the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality (AHRQ) from 2008 to 2020 to calculate nationally weighted estimates for both conditions by ICD-9 and ICD-10 diagnosis codes. We used several statistical measures, including descriptive statistics with design-based chi-square and t-tests, trend analysis with Cochran-Armitage test, generalized linear models, and other data preprocessing measures.
Results: A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold). Most of the hospitalized patients were males (59.16%), aged 41-64 (45.77%), White (68.64%), from the West (53.09%), with Medicaid (50.48%), and with median income <$25,000. The rate of increase over the period was higher for males (11.8-fold), race (not sure which race; please check and modify), aged 41-64 (11.3-fold), and in the South (15.1-fold). An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19-33.22) compared to non-users. With respective reference categories, the significantly higher PR was evident for males, patients aged 41-64, White, with Medicare, median income <$25,000, all regions compared to Northeast, length of hospital stays, and conditions, including chronic pulmonary disease, diabetes, hypertension, obesity, and peripheral vascular disorders.
Conclusion: This study reveals a national overall and demographic-specific trend of increasing PAH with concurrent methamphetamine usage and associated factors. The findings may help to understand the current patterns and identify the vulnerable sociodemographic cohorts for further research and to take appropriate policy measures.
{"title":"Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study.","authors":"Amanda Husein, Jolie Boullion, Md Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, Md Shenuarin Bhuiyan, Gopi K Kolluru, Md Mostafizur Rahman Bhuiyan, Nicholas E Goeders, Steven A Conrad, John A Vanchiere, A Wayne Orr, Christopher G Kevil, Mohammad Alfrad Nobel Bhuiyan","doi":"10.3389/fcvm.2024.1445193","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1445193","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive form of pulmonary hypertension in which increased arterial pressure causes remodeling of the arterial system and is associated with heart failure. Methamphetamine is a stimulant that has recently become a focus in PAH research, but the recent trends and demographics of this cohort of patients are not known. The study aimed to analyze the overall trends and demographics of PAH patients with and without concurrent methamphetamine usage.</p><p><strong>Methods: </strong>The study used the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), and Agency for Healthcare Research and Quality (AHRQ) from 2008 to 2020 to calculate nationally weighted estimates for both conditions by ICD-9 and ICD-10 diagnosis codes. We used several statistical measures, including descriptive statistics with design-based chi-square and <i>t</i>-tests, trend analysis with Cochran-Armitage test, generalized linear models, and other data preprocessing measures.</p><p><strong>Results: </strong>A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold). Most of the hospitalized patients were males (59.16%), aged 41-64 (45.77%), White (68.64%), from the West (53.09%), with Medicaid (50.48%), and with median income <$25,000. The rate of increase over the period was higher for males (11.8-fold), race (not sure which race; please check and modify), aged 41-64 (11.3-fold), and in the South (15.1-fold). An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19-33.22) compared to non-users. With respective reference categories, the significantly higher PR was evident for males, patients aged 41-64, White, with Medicare, median income <$25,000, all regions compared to Northeast, length of hospital stays, and conditions, including chronic pulmonary disease, diabetes, hypertension, obesity, and peripheral vascular disorders.</p><p><strong>Conclusion: </strong>This study reveals a national overall and demographic-specific trend of increasing PAH with concurrent methamphetamine usage and associated factors. The findings may help to understand the current patterns and identify the vulnerable sociodemographic cohorts for further research and to take appropriate policy measures.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1445193"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1433227
Kensuke Nishimiya, Gargi Sharma, Kanwarpal Singh, Osman O Ahsen, Joseph A Gardecki, Guillermo J Tearney
Introduction: Birefringent crystals such as monosodium-urate (MSU) and cholesterol crystals (CC) likely contribute to the progression of coronary artery disease (CAD) due to their potential to exacerbate inflammation through inflammatory cytokine activation. Here, we present cross-polarized micro-optical coherence tomography (CP-µOCT) for visualizing individual birefringent crystals in human coronary arteries.
Methods and results: Human cadaver coronary arteries with a history of CAD with or without gout were dissected for CP-µOCT imaging. Specimens were processed for histological identification of birefringence under polarization light microscopy (PLM). CP-µOCT visualized needle-crystals that appeared as long projections in orthogonal planes, and PLM confirmed that CP-µOCT-delineated needle-crystals demonstrated negative birefringence. The needle-crystals were dissolved after immersion in uricase (p < 0.05), and thus were MSU. CP-µOCT was three-dimensionally volume-rendered for counting MSU and CCs in 79 regions of interest sized [750 (x) × 500 (y) × 400 (z) µm]. Crystal counts were normalized by the total coronary length utilized. The relationship between CP-µOCT-delineated MSU counts and those seen in corresponding histology, and the difference in coronary MSU amongst gout vs. non-gout patients was analyzed. CP-µOCT-delineated MSU counts were significantly correlated with MSU counted by PLM-based histology (R = 0.98, p < 0.01), and with histology-derived intimal thickening (R = 0.51, p < 0.01). MSU and CCs were both significantly greater in gout patients compared with non-gout patients (p < 0.05).
Discussion: These results demonstrate a significant increase in CP-µOCT-delineated crystals in gout vs. non-gout patients, suggesting that this technology can be used to improve our understanding of crystal-driven coronary pathogenesis.
{"title":"Imaging human coronary cholesterol/urate crystals with cross-polarized micro-optical coherence tomography.","authors":"Kensuke Nishimiya, Gargi Sharma, Kanwarpal Singh, Osman O Ahsen, Joseph A Gardecki, Guillermo J Tearney","doi":"10.3389/fcvm.2024.1433227","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1433227","url":null,"abstract":"<p><strong>Introduction: </strong>Birefringent crystals such as monosodium-urate (MSU) and cholesterol crystals (CC) likely contribute to the progression of coronary artery disease (CAD) due to their potential to exacerbate inflammation through inflammatory cytokine activation. Here, we present cross-polarized micro-optical coherence tomography (CP-µOCT) for visualizing individual birefringent crystals in human coronary arteries.</p><p><strong>Methods and results: </strong>Human cadaver coronary arteries with a history of CAD with or without gout were dissected for CP-µOCT imaging. Specimens were processed for histological identification of birefringence under polarization light microscopy (PLM). CP-µOCT visualized needle-crystals that appeared as long projections in orthogonal planes, and PLM confirmed that CP-µOCT-delineated needle-crystals demonstrated negative birefringence. The needle-crystals were dissolved after immersion in uricase (<i>p</i> < 0.05), and thus were MSU. CP-µOCT was three-dimensionally volume-rendered for counting MSU and CCs in 79 regions of interest sized [750 (<i>x</i>) × 500 (<i>y</i>) × 400 (<i>z</i>) µm]. Crystal counts were normalized by the total coronary length utilized. The relationship between CP-µOCT-delineated MSU counts and those seen in corresponding histology, and the difference in coronary MSU amongst gout vs. non-gout patients was analyzed. CP-µOCT-delineated MSU counts were significantly correlated with MSU counted by PLM-based histology (<i>R</i> = 0.98, <i>p</i> < 0.01), and with histology-derived intimal thickening (<i>R</i> = 0.51, <i>p</i> < 0.01). MSU and CCs were both significantly greater in gout patients compared with non-gout patients (<i>p</i> < 0.05).</p><p><strong>Discussion: </strong>These results demonstrate a significant increase in CP-µOCT-delineated crystals in gout vs. non-gout patients, suggesting that this technology can be used to improve our understanding of crystal-driven coronary pathogenesis.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1433227"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-28eCollection Date: 2024-01-01DOI: 10.3389/fcvm.2024.1442800
Ken Nakamura, Kimihiro Kobayashi, Shingo Nakai, Ri Sho, Shusuke Arai, Ai Ishizawa, Daisuke Watanabe, Shuto Hirooka, Eiichi Ohba, Masahiro Mizumoto, Yoshinori Kuroda, Cholsu Kim, Hideaki Uchino, Takao Shimanuki, Tetsuro Uchida
Objective: Preemptive thoracic endovascular aortic repair (TEVAR) has the potential to improve the prognosis of Stanford type B aortic dissection (TBAD), however it is important to determine whether it could be safely performed as a prophylactic treatment. This study aimed to determine the short- and long-term outcomes of preemptive TEVAR for uncomplicated TBAD with a small aortic aneurysm.
Design: Retrospective multicenter analysis.
Methods: We analyzed 212 patients with medically treated uncomplicated subacute TBAD between July 2004 and October 2019 in two Japanese academic centers. The short- and long-term prognosis of patients who underwent preemptive TEVAR and the changes in aortic diameter over time after TEVAR were analyzed. Aorta-related complications, aortic-related death and postoperative complications were recorded and analyzed. Analysis was performed on an intension-to-treat basis.
Results: During follow-up, patients were divided into two groups: optimal medical treatment [OMT; n = 185 (87%)] and preemptive TEVAR [n = 27 (13%)]. In all cases, aortic enlargement was the reason for therapeutic intervention in the preemptive TEVAR group. Propensity score matching yielded a cohort of 27 control patients with OMT (group A) and 27 patients who underwent preemptive TEVAR (group B). Preoperative characteristics were similar between groups. In group B, only one patient developed type A dissection at a late stage and died from aortic rupture. Freedom from aortic-related death at 1/5/10 years was 100%/92%/92% in group B. Overall growth (mm/year) of max aorta was significantly smaller in the TEVAR group than in the control group (-3.7 ± 2.9 vs. 0.4 ± 5.6, p < 0.01), and the diameter of the false lumen was reduced (-8 ± 4.8 vs. -1.3 ± 8.0, p < 0.001).
Conclusions: Short- and long-term outcomes of TEVAR for uncomplicated TBAD with a small aortic aneurysm were excellent, with few postoperative complications. After TEVAR, aortic remodeling was observed in the short term, suggesting that it may contribute to the prevention of aortic-related death due to rupture.
目的:先发制人的胸腔内血管主动脉修复术(TEVAR)有可能改善斯坦福B型主动脉夹层(TBAD)的预后,但重要的是确定其是否能作为预防性治疗安全实施。本研究旨在确定对伴有小主动脉瘤的无并发症TBAD进行先期TEVAR治疗的短期和长期疗效:设计:回顾性多中心分析:我们分析了2004年7月至2019年10月期间在日本两个学术中心接受药物治疗的212名无并发症亚急性TBAD患者。分析了先行 TEVAR 患者的短期和长期预后,以及 TEVAR 后主动脉直径随时间的变化。记录并分析了主动脉相关并发症、主动脉相关死亡和术后并发症。分析以意向治疗为基础:随访期间,患者被分为两组:最佳药物治疗[OMT;n = 185(87%)]和先期TEVAR[n = 27(13%)]。在所有病例中,主动脉扩大是先发制人 TEVAR 组进行治疗干预的原因。倾向得分匹配得出的队列包括 27 名接受 OMT 的对照组患者(A 组)和 27 名接受先发制人 TEVAR 的患者(B 组)。两组患者的术前特征相似。在 B 组中,只有一名患者在晚期出现 A 型夹层,死于主动脉破裂。TEVAR组的最大主动脉总体增长(毫米/年)明显小于对照组(-3.7 ± 2.9 vs. 0.4 ± 5.6,p p 结论:TEVAR治疗无并发症的TBAD和小主动脉瘤的短期和长期疗效都很好,术后并发症很少。TEVAR 术后短期内可观察到主动脉重塑,这表明 TEVAR 有助于预防主动脉破裂导致的死亡。
{"title":"Safe and favorable prognosis of thoracic endovascular aortic repair for the low-risk patients with non-acute type B aortic dissection.","authors":"Ken Nakamura, Kimihiro Kobayashi, Shingo Nakai, Ri Sho, Shusuke Arai, Ai Ishizawa, Daisuke Watanabe, Shuto Hirooka, Eiichi Ohba, Masahiro Mizumoto, Yoshinori Kuroda, Cholsu Kim, Hideaki Uchino, Takao Shimanuki, Tetsuro Uchida","doi":"10.3389/fcvm.2024.1442800","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1442800","url":null,"abstract":"<p><strong>Objective: </strong>Preemptive thoracic endovascular aortic repair (TEVAR) has the potential to improve the prognosis of Stanford type B aortic dissection (TBAD), however it is important to determine whether it could be safely performed as a prophylactic treatment. This study aimed to determine the short- and long-term outcomes of preemptive TEVAR for uncomplicated TBAD with a small aortic aneurysm.</p><p><strong>Design: </strong>Retrospective multicenter analysis.</p><p><strong>Methods: </strong>We analyzed 212 patients with medically treated uncomplicated subacute TBAD between July 2004 and October 2019 in two Japanese academic centers. The short- and long-term prognosis of patients who underwent preemptive TEVAR and the changes in aortic diameter over time after TEVAR were analyzed. Aorta-related complications, aortic-related death and postoperative complications were recorded and analyzed. Analysis was performed on an intension-to-treat basis.</p><p><strong>Results: </strong>During follow-up, patients were divided into two groups: optimal medical treatment [OMT; <i>n</i> = 185 (87%)] and preemptive TEVAR [<i>n</i> = 27 (13%)]. In all cases, aortic enlargement was the reason for therapeutic intervention in the preemptive TEVAR group. Propensity score matching yielded a cohort of 27 control patients with OMT (group A) and 27 patients who underwent preemptive TEVAR (group B). Preoperative characteristics were similar between groups. In group B, only one patient developed type A dissection at a late stage and died from aortic rupture. Freedom from aortic-related death at 1/5/10 years was 100%/92%/92% in group B. Overall growth (mm/year) of max aorta was significantly smaller in the TEVAR group than in the control group (-3.7 ± 2.9 vs. 0.4 ± 5.6, <i>p</i> < 0.01), and the diameter of the false lumen was reduced (-8 ± 4.8 vs. -1.3 ± 8.0, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Short- and long-term outcomes of TEVAR for uncomplicated TBAD with a small aortic aneurysm were excellent, with few postoperative complications. After TEVAR, aortic remodeling was observed in the short term, suggesting that it may contribute to the prevention of aortic-related death due to rupture.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1442800"},"PeriodicalIF":2.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}